MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
- First Posted Date
- 2006-02-06
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 35
- Registration Number
- NCT00287079
- Locations
- 🇨🇦
Canadian Medical Information Office, Windsor, Barrie, Hamilton, Mississauga, Ontario, Canada
Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN®
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 318
- Registration Number
- NCT00256126
- Locations
- 🇬🇧
Local Medical Information Office, Feltham, United Kingdom
🇫🇷Local Medical InformationOffice, Paris, France
CLEAR Study: Clinical Experience Acquired With Raptiva Study
Phase 3
Completed
- Conditions
- Moderate to Severe Psoriasis
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2017-01-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 793
- Registration Number
- NCT00256139
- Locations
- 🇨🇭
Serono International SA, Geneva, Switzerland
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
Phase 4
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1266
- Registration Number
- NCT00249808
- Locations
- 🇬🇧
Medical Information, Feltham, United Kingdom
Safety and Efficacy of Pre-defined, Fixed Dose of Gonal-f Pen Based on Subject Baseline Characteristics in Subjects Undergoing in Vitro Fertilization (IVF)
Phase 4
Completed
- Conditions
- Infertility
- Interventions
- Drug: Recombinant human chorionic gonadotrophin (r-hCG)
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 166
- Registration Number
- NCT00249834
- Locations
- 🇫🇷
Medical Information, Paris, France
Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2017-09-26
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 22
- Registration Number
- NCT00249821
Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer
Phase 2
Completed
- Conditions
- Esophageal CancerGastric Cancer
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 72
- Registration Number
- NCT00215644
- Locations
- 🇬🇧
Research Site, Portsmouth, United Kingdom
Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)
Phase 2
Completed
- Conditions
- Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
- Interventions
- Biological: Tecemotide (L-BLP25)Other: Best Supportive Care (BSC)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 171
- Registration Number
- NCT00157209
- Locations
- 🇩🇪
Please Contact the Merck KGaA Communication Center, Darmstadt, Germany
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Phase 2
Completed
- Conditions
- Lung NeoplasmsCarcinoma, Non-Small-Cell Lung
- Interventions
- Biological: Tecemotide (L-BLP25)Other: Best standard of care (BSC)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2015-08-18
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 22
- Registration Number
- NCT00157196
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
Phase 3
Completed
- Conditions
- Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
- Interventions
- Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1221
- Registration Number
- NCT00154102
- Locations
- 🇫🇷
Research Sites, Nantes, France
🇬🇧Research Site, Sutton, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath